

## **Prolia**

Procedural steps taken and scientific information after the authorisation\*

\*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to **EPAR - Procedural steps taken and scientific information after authorisation (archive)**.

Application number	Scope	Opinion/ Notification <sup>1</sup> issued on	Product Information affected <sup>3</sup>	Summary
Variation type IB /	C.I.3 Change(s) in the Summary of Product	17/06/2025	SmPC	

<sup>&</sup>lt;sup>1</sup> Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.



<sup>&</sup>lt;sup>2</sup> A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

<sup>&</sup>lt;sup>3</sup> SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

EMA /\/D /CCC	20267200	Characteristics taballines as Basic
EMA/VR/000	0026/398	Characteristics, Labelling or Package Leaflet
		of human medicinal products intended to
		implement the outcome of a procedure
		concerning PSUR or PASS, or the outcome of
		the assessment done by the competent
		authority under Articles 45 or 46 of
		Regulation 1901/2006 - C.I.3.z
		Implementation of wording agreed by the
		competent authority that require additional
		minor assessment, e.g. translations are not
		yet agreed upon - Accepted
		, , , ,
		C.I.3.z - To update section 5.1 of the SmPC
		to include the wording agreed following
		finalisation of procedure
		EMEA/H/C/001120/P46/045. In addition,
		the marketing authorisation holder has taken
		the opportunity to implement minor editorial
		changes in the SmPC.